Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 215Precursor Cell Lymphoblastic Leukemia-Lymphoma 188Lymphoma, Large B-Cell, Diffuse 172Leukemia 102Burkitt Lymphoma 91Lymphoma, Non-Hodgkin 89Lymphoma, Follicular 78Lymphoma, Mantle-Cell 53Neuroblastoma 51Hodgkin Disease 46Central Nervous System Neoplasms 42Sarcoma 37Lymphoma, B-Cell 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large-Cell, Anaplastic 29Recurrence 28Lymphoma, T-Cell, Peripheral 28Lymphoma, Large-Cell, Immunoblastic 27Rhabdomyosarcoma 25Neoplasms 25Multiple Myeloma 24Medulloblastoma 22Lymphoma, B-Cell, Marginal Zone 22Leukemia, Lymphocytic, Chronic, B-Cell 21Leukemia, Biphenotypic, Acute 21Brain Neoplasms 20Sarcoma, Ewing 18Retinoblastoma 18Lymphoma, T-Cell 17HIV Infections 17

Interventions

Rituximab 4Etoposide 4Cyclophosphamide 4Vincristine 3Prednisone 3Doxorubicin 3liposomal doxorubicin 2varlilumab 1prednylidene 1pomalidomide 1fialuridine 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Primary Effusion × Vincristine × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡